CAR T Cells Surface-Conjugated Nanoparticles Solid Tumor Microenvironment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Adoptive CAR-T cell therapy faces limitations in treating solid tumors due to the suppressive tumor microenvironment, where high concentrations of adenosine inhibit T cell function, leading to rapid loss of effector functions and reduced therapeutic efficacy.
Innovation Solution
Engineered CAR T cells are surface-conjugated with drug-loaded nanoparticles, specifically cross-linked multilamellar liposomes encapsulating A2a receptor antagonists like SCH58261, to maintain T cell function and persistence within the tumor microenvironment, enhancing anti-tumor immunity by blocking immunosuppressive pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cells are transferred to treat solid tumors, then anti-tumor immunity is enhanced, but T cell effector function is rapidly lost due to immunosuppressive tumor microenvironment
Solution Approach 1:
The patent applies preliminary action by pre-loading nanoparticles with immunosuppression-blocking drugs and conjugating them to CAR T cells before transfer. This ensures that the T cells are equipped with protective mechanisms in advance, allowing them to resist tumor microenvironment suppression from the outset and maintain effector function throughout the therapeutic process.
2Reliability
If small-molecule A2aR antagonists are administered systemically, then T cell function is improved, but drug solubility and sustained circulation are insufficient
Solution Approach 1:
The patent uses nanoparticles as intermediaries to deliver A2aR antagonists. The nanoparticles serve as a carrier that solves the solubility problem of small-molecule drugs and provides sustained release capability. The conjugation to CAR T cells further ensures targeted delivery and prolonged local circulation within the tumor microenvironment, overcoming the limitations of systemic administration.
3Quantity of substance
If nanoparticles are administered to deliver drugs to tumors, then targeted delivery is improved, but most nanoparticles accumulate in organs other than tumor
Solution Approach 1:
The patent employs CAR T cells as active intermediaries that actively navigate to and infiltrate tumor tissue. By conjugating nanoparticles to these living targeting cells, the system combines the active homing capability of CAR T cells with the drug delivery function of nanoparticles, significantly improving tumor specificity and reducing off-target accumulation compared to passive nanoparticle delivery alone.
Solution Approach 2:
The patent merges the targeting function of CAR T cells with the drug delivery function of nanoparticles into a single integrated system. This combination allows the nanoparticle-conjugated T cells to simultaneously perform immune surveillance, active tumor targeting, and sustained drug delivery, thereby improving tumor drug concentration while minimizing accumulation in non-target organs.
Data Source
Figure 1A~1E
Figure 2A~2D
Figure 2E~2F
AI summary
Described herein are compositions including an immune effector cells that are chemically modified at the surface with one or more active agent-loaded nano- or micro-particles for controlled release of the active agent. Exemplary drug-loaded nanoparticles include crosslinked multilayer liposome (CMLV) encapsulating an A2a receptor inhibitor. The modified immune effector cells may also present one or more chimeric antigen receptors (CARs) on the surface. Also provided are methods of using the same to treat cancer.